KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Return on Equity: 2011-2025

Historic Return on Equity for Novavax (NVAX) over the last 13 years, with Sep 2025 value amounting to -5.74%.

  • Novavax's Return on Equity fell 634.00% to -5.74% in Q3 2025 from the same period last year, while for Sep 2025 it was -5.74%, marking a year-over-year decrease of 634.00%. This contributed to the annual value of 0.28% for FY2024, which is 53.00% down from last year.
  • Latest data reveals that Novavax reported Return on Equity of -5.74% as of Q3 2025, which was up 74.19% from -22.24% recorded in Q2 2025.
  • In the past 5 years, Novavax's Return on Equity ranged from a high of 9.20% in Q1 2022 and a low of -31.80% during Q4 2021.
  • Over the past 3 years, Novavax's median Return on Equity value was 0.50% (recorded in 2024), while the average stood at -2.16%.
  • Per our database at Business Quant, Novavax's Return on Equity crashed by 3,066bps in 2021 and then surged by 3,290bps in 2022.
  • Quarterly analysis of 5 years shows Novavax's Return on Equity stood at -31.80% in 2021, then soared by 3,290bps to 1.10% in 2022, then plummeted by 32bps to 0.78% in 2023, then crashed by 46bps to 0.33% in 2024, then tumbled by 634bps to -5.74% in 2025.
  • Its Return on Equity was -5.74% in Q3 2025, compared to -22.24% in Q2 2025 and -1.37% in Q1 2025.